Department of Nursing, College of Health Science, Debre Berhan University, Ethiopia.
Department pre-clinical, College of Medicine, Debre Berhan University, Ethiopia.
Afr Health Sci. 2022 Jun;22(2):12-26. doi: 10.4314/ahs.v22i2.3.
BACKGROUND: Patients who are lost to follow-up while on treatment compromise their own health and the long-term success of antiretroviral therapy (ART) programs. Besides, loss to follow-up (LTFU) increases HIV-related morbidity and mortality. Therefore, this study aimed to determine the incidence of LTFU and its predictors among adult HIV positive patients on anti-retroviral therapy at North Shoa zone public hospitals, Northeast Ethiopia. METHODS: A retrospective follow up study of 517 people living with HIV/AIDS and attending an ART clinic between 2015 and 2020 was conducted at North Shewa zone, public hospitals. Kaplan-Meier failure function together with log rank test was used to compare failure function. Multivariable Cox proportion hazards regression model was used to determine predictors of LTFU. RESULT: The incidence density rate of lost to follow up among HIV positive adult on ART was found to be 8.9 per 100 adult years observation (95%CI; 7.45, 10.68). In multivariable cox proportional regression analysis, WHO clinical stage-IV (AHR = 1.50; 95% CI: 1.08, 3.75), comorbidity disease (AHR = 0.54; 95% CI; 0.30, 0.97), body mass index less than 18kg/m2 (AHR = 1.60; 95% CI; 1.02, 2.51), cotrimoxazole preventive therapy (AHR = 1.57; 95% CI;1.09, 2.53), and a low CD4 count (AHR = 1.66; 95% CI; 1.29, 3.49) were found to be a significant predictors of lost to follow up. CONCLUSION: The current study showed that the incidence rate of loss to ART follow-up was high. Body mass index score less than 18kg/m2, advanced WHO clinical stage, CD4<200cell/mm, had comorbidity disease, and cotrimoxazole therapy were a significant predictors of lost to ART follow up. Therefore, appropriate mitigation measures in the at-risk group need to be instigated to advance retention rate.
背景:在接受治疗过程中失去随访的患者会危及自身健康,并影响抗逆转录病毒疗法(ART)项目的长期成功。此外,失访(LTFU)会增加与 HIV 相关的发病率和死亡率。因此,本研究旨在确定东北埃塞俄比亚北绍阿地区公立医院接受抗逆转录病毒治疗的成年 HIV 阳性患者的 LTFU 发生率及其预测因素。
方法:对 2015 年至 2020 年期间在北绍阿地区公立医院接受 ART 门诊治疗的 517 名 HIV 感染者/艾滋病患者进行了回顾性随访研究。Kaplan-Meier 失效功能与对数秩检验用于比较失效功能。多变量 Cox 比例风险回归模型用于确定 LTFU 的预测因素。
结果:ART 治疗中 HIV 阳性成年患者的失访发生率密度为每 100 成人年观察 8.9 例(95%CI;7.45,10.68)。在多变量 Cox 比例风险回归分析中,世界卫生组织(WHO)临床分期-IV(AHR=1.50;95%CI:1.08,3.75)、合并症(AHR=0.54;95%CI;0.30,0.97)、体重指数小于 18kg/m2(AHR=1.60;95%CI;1.02,2.51)、复方新诺明预防治疗(AHR=1.57;95%CI;1.09,2.53)和低 CD4 计数(AHR=1.66;95%CI;1.29,3.49)被发现是失访的显著预测因素。
结论:本研究表明,ART 随访失访率较高。体重指数评分小于 18kg/m2、WHO 临床分期较晚、CD4<200 个细胞/mm、合并症和复方新诺明治疗是 ART 随访失访的显著预测因素。因此,需要在高危人群中采取适当的缓解措施来提高保留率。